Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review

British Journal of Clinical Pharmacology

Volumn 80, Issue 2, 2015, Pages 200-208

  Cohen, Shlomi ^a,b   Bueno De Mesquita, Mirjam ^a,b   Mimouni, Francis B ^b,c  

^a Pediatric Gastroenterology unit 'Dana Dwek' Children's Hospital Aviv Medical Center   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

antacids; children; gastroesophageal reflux disease; histamine H2< inf> receptor antagonists; metoclopramide; prokinetics; proton pump inhibitors

Indexed keywords

ALGINIC ACID; BACLOFEN; BETHANECHOL; CIMETIDINE; CISAPRIDE; DOMPERIDONE; ERYTHROMYCIN; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METOCLOPRAMIDE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ACCIDENTAL INJURY; ACUTE PANCREATITIS; ADVERSE DRUG REACTION; ANEMIA; ANOREXIA; APNEA; ARTHRALGIA; ASTHMA; BRONCHITIS; CHEST TIGHTNESS; CHILDHOOD DISEASE; CHILL; CONSTIPATION; COUGHING; DIARRHEA; DIZZINESS; DROWSINESS; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG USE; DYSMENORRHEA; DYSTONIA; DYSTONIC DISORDER; ECZEMA; FATIGUE; FLATULENCE; FOOD REGURGITATION; GALACTORRHEA; GASTRITIS; GASTROENTERITIS; GASTROESOPHAGEAL REFLUX; HAIR LOSS; HEART ARRHYTHMIA; HEART MURMUR; HEPATITIS; HOT FLUSH; HUMAN; HYPERGASTRINEMIA; INFECTION RISK; INTESTINE VOLVULUS; IRRITABILITY; NAUSEA; OCULOGYRIC CRISIS; OTITIS MEDIA; PERIORBITAL EDEMA; PHARYNGITIS; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SICKLE CELL ANEMIA; SINUSITIS; SOMNOLENCE; SORE THROAT; SYSTEMATIC REVIEW; TOOTH DISCOLORATION; TOOTH PAIN; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VOMITING; ADOLESCENT; CHILD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FACTUAL DATABASE; INFANT; NEWBORN; PRESCHOOL CHILD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; INFANT; INFANT, NEWBORN; PROTON PUMP INHIBITORS;

EID: 84937432280     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12619     Document Type: Review

References (76)

1. Hegar B, Dewanti NR, Kadim M, Alatas S, Firmansyah A, Vandenplas Y,. Natural evolution of regurgitation in healthy infants. Acta Paediatr 2009; 98: 1189-93.
2. Sherman PM, Hassall E, Fagundes-Neto U, Gold BD, Kato S, Koletzko S, Orenstein S, Rudolph C, Vakil N, Vandenplas Y,. A global, evidence-based consensus on the definition of gastroesphageal reflux disease in the pediatric population. Am J Gastroenterol 2009; 104: 1278-95.
3. Ward RM, Kearns GL,. Proton pump inhibitors in pediatrics: mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatr Drugs 2013; 15: 119-31.
4. Lind T, Rydberg L, Kyleback A, Jonsson A, Andersson T, Hasselgren G, Holmberg J, Röhss K,. Esomeprazole provides improved acid control vs. omeprazole inpatients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 861-7.
5. Davidson G, Wenzl TG, Thomson M, Omari T, Barker P, Lundborg P, Illueca M,. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. J Pediatr 2013; 163: 692-8.e1-2.
6. Sandström M, Davidson G, Tolia V, Sullivan JE, Långström G, Lundborg P, Brown K,. Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17years of age. Clin Ther 2012; 34: 1828-38.
7. Winter H, Gunasekaran T, Tolia V, Gottrand F, Barker PN, Illueca M,. Esomeprazole for the treatment of GERD in infants ages 1-11 months. J Pediatr Gastroenterol Nutr 2012; 55: 14-20.
8. Tolia V, Gilger MA, Barker PN, Illueca M,. Healing of erosive esophagitis and improvement of symptoms of gastroesophageal reflux disease after esomeprazole treatment in children 12 to 36months old. J Pediatr Gastroenterol Nutr 2010; 51: 593-8.
9. Tolia V, Youssef NN, Gilger MA, Traxler B, Illueca M,. Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. BMC Pediatr 2010; 10: 41.
10. Omari T, Lundborg P, Sandström M, Bondarov P, Fjellman M, Haslam R, Davidson G,. Pharmacodynamics and systemic exposure of esomeprazole in preterm infants and term neonates with gastroesophageal reflux disease. J Pediatr 2009; 155: 222-8.
11. Gilger MA, Tolia V, Vandenplas Y, Youssef NN, Traxler B, Illueca M,. Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2008; 46: 524-33.
12. Omari T, Davidson G, Bondarov P, Nauclér E, Nilsson C, Lundborg P,. Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2007; 45: 530-7.
13. Gold BD, Gunasekaran T, Tolia V, Wetzler G, Conter H, Traxler B, Illueca M,. Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2007; 45: 520-9.
14. Baldassarre E, Sagaon MM, Ferrarini A, Bianchetti MG,. Severe systemic adverse reaction to proton pump inhibitors in an infant. Pediatr Pulmonol 2007; 42: 563-4.
15. Zhao J, Li J, Hamer-Maansson JE, Andersson T, Fulmer R, Illueca M, Lundborg P,. Pharmacokinetic properties of esomeprazole in children aged 1 to 11years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clin Ther 2006; 28: 1868-76.
16. Li J, Zhao J, Hamer-Maansson JE, Andersson T, Fulmer R, Illueca M, Lundborg P,. Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clin Ther 2006; 28: 419-27.
17. Ummarino D, Miele E, Masi P, Tramontano A, Staiano A, Vandenplas Y,. Impact of antisecretory treatment on respiratory symptoms of gastroesophageal reflux disease in children. Dis Esophagus 2012; 25: 671-7.
18. Hassall E, Shepherd R, Koletzko S, Radke M, Henderson C, Lundborg P,. Long-term maintenance treatment with omeprazole in children with healed erosive oesophagitis: a prospective study. Aliment Pharmacol Ther 2012; 35: 368-79.
19. Tuleu C, Arenas-Lopez S, Robinson C, McCarthy D, Paget RI, Tibby S, Taylor KM,. 'Poppy seeds' in stomach aspirates: is oral omeprazole extemporaneous dispersion bioavailable? Eur J Pediatr 2008; 167: 823-5.
20. Bishop J, Furman M, Thomson M,. Omeprazole for gastroesophageal reflux disease in the first 2years of life: a dose-finding study with dual-channel pH monitoring. J Pediatr Gastroenterol Nutr 2007; 45: 50-5.
21. Baldassarre E, Sagaon MM, Ferrarini A,. Severe systemic adverse reaction to proton pump inhibitors in an infant. Pediatr Pulmonol 2007; 42: 563-4.
22. Boccia G, Manguso F, Miele E, Buonavolontà R, Staiano A,. Maintenance therapy for erosive esophagitis in children after healing by omeprazole: is it advisable? Am J Gastroenterol 2007; 102: 1291-7.
23. Omari TI, Haslam RR, Lundborg P, Davidson GP,. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux. J Pediatr Gastroenterol Nutr 2007; 44: 41-4.
24. Canani RB, Cirillo P, Roggero P, Romano C, Malamisura B, Terrin G, Passariello A, Manguso F, Morelli L, Guarino A,; Working Group on Intestinal Infections of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP). Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006; 117: e817-20.
25. Orel R, Brecelj J, Homan M, Heuschkel R,. Treatment of oesophageal bile reflux in children: the results of a prospective study with omeprazole. J Pediatr Gastroenterol Nutr 2006; 42: 376-83.
26. Størdal K, Johannesdottir GB, Bentsen BS, Knudsen PK, Carlsen KC, Closs O, Handeland M, Holm HK, Sandvik L,. Acid suppression does not change respiratory symptoms in children with asthma and gastro-oesophageal reflux disease. Arch Dis Child 2005; 90: 956-60.
27. Holbrook JT, Wise RA, Gold BD, Blake K, Brown ED, Castro M, Dozor AJ, Lima JJ, Mastronarde JG, Sockrider MM, Teague WG,. Writing Committee for the American Lung Association Asthma Clinical Research Centers. Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. JAMA 2012; 307: 373-81.
28. Kukulka M, Wu J, Perez MC J,. Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD. J Pediatr Gastroenterol Nutr 2012; 54: 41-7.
29. Eren M, Ybox drawings light down and leftldbox drawings light down and leftrbox drawings light down and leftm SH, Sivrikoz IA,. Safety profile of six months lansoprozole treatment in children. Indian J Gastroenterol 2010; 29: 247-8.
30. Lee JH, Kim MJ, Lee JS, Choe YH,. The effects of three alternative treatment strategies after 8weeks of proton pump inhibitor therapy for GERD in children. Arch Dis Child 2011; 96: 9-13.
31. Orenstein SR, Hassall E, Furmaga-Jablonska W, Atkinson S, Raanan M,. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr 2009; 154: 514-20.
32. Springer M, Atkinson S, North J, Raanan M,. Safety and pharmacodynamics of lansoprazole in patients with gastroesophageal reflux disease aged <1year. Paediatr Drugs 2008; 10: 255-63.
33. Khoshoo V, Dhume P,. Clinical response to 2 dosing regimens of lansoprazole in infants with gastroesophageal reflux. J Pediatr Gastroenterol Nutr 2008; 46: 352-4.
34. Heyman MB, Zhang W, Huang B, Chiu YL, Amer F, Winter HS,. Pharmacokinetics and pharmacodynamics of lansoprazole in children 13 to 24months old with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2007; 44: 35-40.
35. Fiedorek S, Tolia V, Gold BD, Huang B, Stolle J, Lee C, Gremse D,. Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2005; 40: 319-27.
36. Das S, Ganguly A, Ghosh A, Mondal S, Dey JK, Saha I,. Oral pantoprazole-induced acute pancreatitis in an 11-year-old child. Ther Drug Monit 2012; 34: 242-4.
37. Tammara BK, Sullivan JE, Adcock KG, Kierkus J, Giblin J, Rath N, Meng X, Maguire MK, Comer GM, Ward RM,. Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1month through <6years with gastro-oesophageal reflux disease. Clin Pharmacokinet 2011; 50: 541-50.
38. Ward RM, Kearns GL, Tammara B, Bishop P, O'Gorman MA, James LP, Katz MH, Maguire MK, Rath N, Meng X, Comer GM,. A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16years with gastroesophageal reflux disease. J Clin Pharmacol 2011; 51: 876-87.
39. Kierkus J, Furmaga-Jablonska W, Sullivan JE, David ES, Stewart DL, Rath N, Fu C, Wang W, Maguire MK, Comer GM,. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1 through 11months with a clinical diagnosis of gastroesophageal reflux disease. Dig Dis Sci 2011; 56: 425-34.
40. Baker R, Tsou VM, Tung J, Baker SS, Li H, Wang W, Rath N, Maguire MK, Comer GM,. Clinical results from a randomized, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5years with symptomatic histologic or erosive esophagitis. Clin Pediatr (Phila) 2010; 49: 852-65.
41. Winter H, Kum-Nji P, Mahomedy SH, Kierkus J, Hinz M, Li H, Maguire MK, Comer GM,. Efficacy and safety of pantoprazole delayed-release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1-11 months old with symptomatic GERD. J Pediatr Gastroenterol Nutr 2010; 50: 609-18.
42. Tolman KG, Taubel J, Warrington S, Chiu YL, Pilmer BL, Pan WJ,. Comparison of the effects of single and repeated oral doses of lansoprazole and rabeprazole on ambulatory 24-hour intragastric pH in healthy volunteers. Clin Drug Invest 2006; 26: 21-8.
43. James L, Walson P, Lomax K, Kao R, Varughese S, Reyes J,. Study 119 Pediatric Trial Investigators. Pharmacokinetics and tolerability of rabeprazole sodium in subjects aged 12 to 16years with gastroesophageal reflux disease: an open-label, single- and multiple-dose study. Clin Ther 2007 29: 2082-92.
44. Zannikos PN, Doose DR, Leitz GJ, Rusch S, Gonzalez MD, Solanki B, Haddad I, Mulberg AE,. Pharmacokinetics and tolerability of rabeprazole in children 1 to 11years old with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2011; 52: 691-701.
45. Joint publication of the British Medical Association, the Royal Pharmaceutical Society of Great Britain, the Royal College of Paediatrics and Child Health, and the Neonatal and Paediatric Pharmacists Group. British National Formulary for Children. Section 1.1.2. London: BMJ Group, 2007: 53.
46. Wheatley E, Kennedy KA,. Cross-over trial of treatment for bradycardia attributed to gastroesophageal reflux in preterm infants. J Pediatr 2009; 155: 516-21.
47. Ameen VZ, Pobiner BF, Giguere GC, Carter EG,. Ranitidine (Zantac) syrup versus ranitidine effervescent tablets (Zantac EFFERdose) in children: a single-center taste preference study. Paediatr Drugs 2006; 8: 265-70.
48. Cucchiara S, Franco MT, Terrin G, Spadaro R, di Nardo G, Iula V,. Role of drug therapy in the treatment of gastro-oesophageal reflux disorder in children. Paediatr Drugs 2000; 2: 263-72.
49. Wenning LA, Murphy MG, James LP, Blumer JL, Marshall JD, Baier J, Scheimann AO, Panebianco DL, Zhong L, Eisenhandler R, Yeh KC, Kearns GL,. Pharmacokinetics of famotidine in infants. Clin Pharmacokinet 2005; 44: 395-406.
50. Furuta S, Kamada E, Suzuki T, Sugimoto T, Kawabata Y, Shinozaki Y, Sano H,. Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole. Xenobiotica 2001; 31: 1-10.
51. Orenstein SR, Gremse DA, Pantaleon CD, Kling DF, Rotenberg KS,. Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: an open-label, multiple-dose, randomized, multicenter clinical trial in 210 children. Clin Ther 2005; 27: 472-83.
52. Eras Z, Oʇuz SS, Dilmen U,. Is metoclopramide safe for the premature infant? Eur Rev Med Pharmacol Sci 2013; 17: 1655-7.
53. Paturi B, Ryan RM, Michienzi KA, Lakshminrusimha S,. Galactorrhea with metoclopramide use in the neonatal unit. J Perinatol 2009; 29: 391-2.
54. Hibbs AM, Lorch SA,. Metoclopramide for the treatment of gastroesophageal reflux disease in infants: a systematic review. Pediatrics 2006; 118: 746-52.
55. Leung AKC, Lai PCW,. Use of metoclopramide for the treatment of gastroesophageal reflux in infants and children. Curr Ther Res Clin Exp 1984; 36: 911-5.
56. Hyams JS, Leichtner AM, Zamett LO, Walters JK,. Effect of metoclopramide on prolonged intraesophageal pH testing in infants with gastroesophageal reflux. J Pediatr Gastroenterol Nutr 1986; 5: 716-20.
57. Glassman M, George D, Grill B,. Gastroesophageal reflux in children. Clinical manifestations, diagnosis and therapy. Gastroenterol Clin North Am 1995; 24: 71-98.
58. Vieira MC, Miyague NI, Van Steen K, Salvatore S, Vandenplas Y,. Effects of domperidone on QTc interval in infants. Acta Paediatr 2012; 101: 494-6.
59. Günlemez A, Babaoʇlu A, Arisoy AE, Türker G, Gökalp AS,. Effect of domperidone on the QTc interval in premature infants. J Perinatol 2010; 30: 50-3.
60. Djeddi D, Kongolo G, Lefaix C, Mounard J, Léké A,. Effect of domperidone on QT interval in neonates. J Pediatr 2008; 153: 663-6.
61. Rocha CM, Barbosa MM,. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol 2005; 26: 720-3.
62. Peeters TL,. Erythromycin and other macrolides as prokinetic agents. Gastroenterology 1993; 105: 1886-99.
63. Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM,. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001; 96: 1698-703.
64. Omari TI, Benninga MA, Sansom L, Butler RN, Dent J, Davidson GP,. Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. J Pediatr 2006; 149: 468-74.
65. Kawai M, Kawahara H, Hirayama S, Yoshimura N, Ida S,. Effect of baclofen on emesis and 24-hour esophageal pH in neurologically impaired children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2004; 38: 317-23.
66. Mandel KG, Daggy BP, Brodie DA,. Review article alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment Pharmacol Ther 2000; 14: 669-90.
67. Corvaglia L, Aceti A, Mariani E, De Giorgi M, Capretti MG, Faldella G,. The efficacy of sodium alginate (Gaviscon) for the treatment of gastro-oesophageal reflux in preterm infants. Aliment Pharmacol Ther 2011; 33: 466-70.
68. Atasay B, Erdeve O, Arsan S, Türmen T,. Effect of sodium alginate on acid gastroesophageal reflux disease in preterm infants: a pilot study. J Clin Pharmacol 2010; 50: 1267-72.
69. Pasqualotto AC, Nedel WL, Machado TS, Severo LC,. A comparative study of risk factors and outcome among outpatient-acquired and nosocomial candidaemia. J Hosp Infect 2005; 60: 129-34.
70. Lightdale JR, Gremse DA,. American Academy of Pediatrics Section on Gastroenterology, Hepatology, and Nutrition. Gastroesophageal reflux: management guidance for the pediatrician. Pediatrics 2013; 131: e1684-95.
71. Moore DJ, Tao BS, Lines DR, Hirte C, Heddle ML, Davidson GP,. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J Pediatr 2003; 143: 219-23.
72. Terrin G, Passariello A, De Curtis M, Manguso F, Salvia G, Lega L, Messina F, Paludetto R, Canani RB,. Ranitidine is associated with infections, necrotizing enterocolitis, and fatal outcome in newborns. Pediatrics 2012; 129: e40-5.
73. Craig WR, Hanlon-Dearman A, Sinclair C, Taback S, Moffatt M,. Metoclopramide, thickened feedings, and positioning for gastro-oesophageal reflux in children under two years. Cochrane Database Syst Rev 2004; (4): CD003502.
74. Vandenplas Y, Rudolph CD, Di Lorenzo C, Hassall E, Liptak G, Mazur L, Sondheimer J, Staiano A, Thomson M, Veereman-Wauters G, Wenzl TG,. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr 2009; 49: 498-547.
75. Smyth RM, Gargon E, Kirkham J, Cresswell L, Golder S, Smyth R, Williamson P,. Adverse drug reactions in children-a systematic review. PLoS One 2012; 7: e24061.
76. Bellis JR, Kirkham JJ, Thiesen S, Conroy EJ, Bracken LE, Mannix HL, Bird KA, Duncan JC, Peak M, Turner MA, Smyth RL, Nunn AJ, Pirmohamed M,. Adverse drug reactions and off-label and unlicensed medicines in children: a nested case-control study of inpatients in a pediatric hospital. BMC Med 2013; 11: 238